Patients of the Massachusetts General Hospital Liver Center have access to leading-edge clinical trials for the treatment of viral hepatitis, including hepatitis B and C, primary biliary cirrhosis, primary sclerosing cholangitis, fatty liver disease and liver cancer.
Lead Clinical Research Coordinator Jenna Gustafson (left) and Pre-liver Transplant Nurse Practitioner Judith Bloom, NP, MSN, meet with a patient
Hepatitis B and C InfectionHepatitis B continues to impact more than 12 million Americans. The Massachusetts General Hospital Liver Center is currently participating in a national study sponsored by the National Institutes of Health to identify factors that impact disease progression. This study will also make available clinical trials with investigational drugs.
Hepatitis C is a chronic infection impacting more than 4 million Americans. Traditionally, treatment for hepatitis C was limited to pegylated interferon and ribavirin, antiviral drugs with significant side effects and only a 50% chance of cure. However, the landscape of hepatitis C treatment is rapidly changing with the hopes of improving cure rates and limiting side effects attributable to interferon. The Mass General Liver Center is participating in a number of innovative treatment trials for hepatitis C including all oral regimens that avoid the use of interferon.
For more information on hepatitis B and C trials, please e-mail LiverResearchGroup@partners.org or call 617-724-3836.Primary Biliary CirrhosisThe Mass General Liver Center is conducting a longitudinal study to evaluate and follow patients with Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC). This study seeks to understand why some adults develop PBC or PSC and the complications of advanced liver disease. In addition, we are active participants in treatment trials for PBC and PSC.
For more information, please e-mail LiverResearchGroup@partners.org or call 617-724-3836.
Non-Alcoholic Fatty Liver DiseaseThe Mass General Liver Center is conducting a longitudinal study to evaluate and follow patients with non-alcoholic fatty liver disease (NAFLD). This study seeks to understand why some adults develop NAFLD and the complications of advanced liver disease. In addition, we are active participants in treatment trials for NAFLD.
For more information, please e-mail LiverResearchGroup@partners.org or call 617-724-3836.Liver CancerThe Mass General Liver Center collaborates with the Mass General Cancer Center on treatment trials for liver and biliary cancer. In addition, both centers are involved in the investigation of novel biomarkers to improve early detection and identification of high-risk markers for hepatocellular carcinoma (HCC).
For more information, please e-mail email@example.com or call 617-724-6006.